Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme

By sjmartinez • June 13, 2023

Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Jun 12:ard-2023-223916. doi: 10.1136/ard-2023-223916. Epub ahead of print. PMID: 37308218.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, methotrexate, Publications, Rheumatology, tumor necrosis factor inhibitors

Assessment of Seroprevalence and Neutralizing Antibodies for Healthcare Worker Protection in a Crimean-Congo Hemorrhagic Fever Endemic Area

Pınarlık F, Karaşahin Ö, Yanık A, Akça D, Sarıkaya Rİ, Güllü D, Arslan EN, Yalçın S, Barlas T, Can FK, Alay H, Özden K, Kuşkucu[...]

Hypertrophic Cardiomyopathy with Left Ventricular Systolic Dysfunction: Integrating Pharmacologic, Device, and Advanced Heart Failure Therapies

Tajdini M, Tavakoli K, Jenkin SC, Keykhaei M, Hahn VS. Hypertrophic Cardiomyopathy with Left Ventricular Systolic Dysfunction: Integrating Pharmacologic, Device, and Advanced Heart Failure Therapies.[...]

Dental malocclusion and associated factors in pet rabbits: a cross-sectional study in Peru (2021-2022)

Masias K, Tejada A, Segura ER, Ormea V. Dental malocclusion and associated factors in pet rabbits: a cross-sectional study in Peru (2021-2022). N Z Vet[...]